Publicação
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.
| dc.contributor.author | Albrecht, P | |
| dc.contributor.author | Bjørnå, K | |
| dc.contributor.author | Brassat, D | |
| dc.contributor.author | Farrell, R | |
| dc.contributor.author | Feys, P | |
| dc.contributor.author | Hobart, J | |
| dc.contributor.author | Hupperts, R | |
| dc.contributor.author | Linnebank, M | |
| dc.contributor.author | Magdič, J | |
| dc.contributor.author | Oreja-Guevara, C | |
| dc.contributor.author | Pozzilli, C | |
| dc.contributor.author | Salgado, AV | |
| dc.contributor.author | Ziemssen, T | |
| dc.date.accessioned | 2018-11-20T10:23:34Z | |
| dc.date.available | 2018-11-20T10:23:34Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and re-treatment, and stopping criteria. This article summarizes the experts' opinions on how PR-fampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248 | pt_PT |
| dc.identifier.doi | 10.1177/1756286418803248. | pt_PT |
| dc.identifier.issn | 1756-2864 | |
| dc.identifier.uri | http://hdl.handle.net/10400.10/2056 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | SAGE Publications | pt_PT |
| dc.relation.publisherversion | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174649/pdf/10.1177_1756286418803248.pdf | pt_PT |
| dc.subject | Multiple sclerosis | pt_PT |
| dc.subject | Quality of life | pt_PT |
| dc.subject | Fampridine | pt_PT |
| dc.title | Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | London | pt_PT |
| oaire.citation.title | Therapeutic advances in neurological disorders. | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |